Merck to acquire Acceleron Pharma, strengthening cardiovascular pipeline

By Rachel Arthur contact

- Last updated on GMT

Merck gains sotatercept and reblozyl with the acquisition. Pic:getty/experienceinteriors
Merck gains sotatercept and reblozyl with the acquisition. Pic:getty/experienceinteriors

Related tags: Merck, cardiovascular disease

Merck (MSD outside the US and Canada) will acquire Acceleron in a deal worth around $11.5bn.

Founded in 2003,  Acceleron works in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. The Cambridge, Massachusetts biotech is focused on the transforming growth factor (TGF)-beta superfamily of proteins that play a central role in the regulation of cell growth, differentiation and repair.

Acceleron’s lead therapeutic candidate, sotatercept, has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder. Sotatercept is in Phase 3 trials as add-on to current standard of care for the treatment of PAH.

In addition, Acceleron’s portfolio includes Reblozyl (luspatercept-aamt), an erythroid maturation recombinant fusion protein approved in the US, Europe, Canada and Australia for the treatment of anemia in certain rare blood disorders. Reblozyl is being developed and commercialized through a global collaboration with Bristol Myers Squibb.

Merck will acquire Acceleron via a subsidiary, with the two merging on completion of the acquisition. The transaction is expected to close in the fourth quarter of 2021.

“Strategic business development is a top priority for Merck as we look to drive sustainable growth and further bolster and balance our pipeline with breakthrough science,”​ said Rob Davis, CEO and president, Merck.

“Acceleron’s innovative research has yielded an exciting late-stage candidate that complements and strengthens our growing cardiovascular portfolio and pipeline and holds the potential to build upon Merck’s proud legacy in cardiovascular disease.”

Related news

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us

Products

View more

Webinars